in this issue
EnviroTech :: Biotech
Merck & Co. and Hanwha Chemical to Develop Biosimilar Candidate
12:03 AM MDT | June 14, 2011 | Deepti Ramesh
Merck & Co. (Whitehouse Station, NJ) says it has entered into an exclusive global agreement with Hanwha Chemical (Seoul) to develop and commercialize a candidate biosimilar form of Enbrel (etanercept). Hanwha Chemical, through its Bio business unit, and Merck, through a subsidiary, will work together to develop and commercialize HD203, a candidate biosimilar form of etanercept developed by Hanwha, under the terms of the agreement. Merck will conduct clinical development and be responsible for manufacturing. Merck will commercialize HD203 globally, except for...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee